Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020178374 - IN VITRO METHOD FOR ASSESSING THE RISK OF PROSTATE SIDE EFFECT AFTER TREATMENT BY IONIZING RADIATION

Publication Number WO/2020/178374
Publication Date 10.09.2020
International Application No. PCT/EP2020/055814
International Filing Date 05.03.2020
IPC
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
CPC
G01N 2510/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2510Detection of programmed cell death, i.e. apoptosis
G01N 2800/40
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
40Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/5014
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
5014for testing toxicity
G01N 33/505
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
5044involving specific cell types
5047Cells of the immune system
505involving T-cells
Applicants
  • NOVAGRAY [FR]/[FR]
  • INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER [FR]/[FR]
  • UNIVERSITÉ DE MONTPELLIER [FR]/[FR]
Inventors
  • FRANC, Clémence
  • AZRIA, David
  • GOURGOU, Sophie
Agents
  • FLESSELLES, Bruno
Priority Data
19305263.606.03.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IN VITRO METHOD FOR ASSESSING THE RISK OF PROSTATE SIDE EFFECT AFTER TREATMENT BY IONIZING RADIATION
(FR) PROCÉDÉ IN VITRO D'ÉVALUATION DU RISQUE D'EFFETS SECONDAIRES DE LA PROSTATE APRÈS TRAITEMENT PAR RAYONNEMENT IONISANT
Abstract
(EN)
The present invention relates to an in vitro method for assessing the risk of developing side effects after ionizing radiation treatment in a prostate cancer subject, comprising the steps of a)determining the presence or absence of urinary toxicity in the patient prior to application of ionizing radiation, b)determining the stage of the tumor, c)optionally determining of at least one other clinical parameter, disease parameter or ionizing radiation treatment parameter from the patient, and d)combining a value associated with the presence of urinary toxicity determined in a), a value associated with the stage of the tumor in b), and a value association with the at least one other clinical parameter, disease parameter or ionizing radiation treatment parameter determined in c) in a mathematical function to obtain an end-value
(FR)
La présente invention concerne un procédé in vitro pour évaluer le risque de développer des effets secondaires après un traitement par rayonnement ionisant dans un sujet atteint d'un cancer de la prostate, comprenant les étapes consistant à a) déterminer la présence ou l'absence de substances toxiques urinaires chez le patient avant l'application d'un rayonnement ionisant, b) déterminer l'étape de la tumeur, c) déterminer de manière facultative au moins un autre paramètre clinique, un paramètre de maladie ou un paramètre de traitement de rayonnement ionisant provenant du patient, et d) combiner une valeur associée à la présence de la toxicité urinaire déterminée en a), une valeur associée à l'étape de la tumeur dans b) et une association de valeurs avec le ou les autres paramètres cliniques, le paramètre de maladie ou le paramètre de traitement de rayonnement ionisant déterminé en c) dans une fonction mathématique pour obtenir une valeur finale.
Also published as
Latest bibliographic data on file with the International Bureau